United Therapeutics Submits Two 'Most Important' NDAs, Q2 Revenue Slips 2%
UTHR sits 78% above its 52-week low of $287.645.
Summary
United Therapeutics reported Q2 revenue of $783.3M, down 2% YoY, missing estimates due to Nebulized Tyvaso weakness, while net income rose 8% to $333M with diluted EPS of $7.27 beating expectations. The company submitted two NDAs—ralinepag tablets for PAH and Nebulized Tyvaso for IPF—which management calls the most important in rare pulmonary disease history. These filings, along with planned INDs and NDAs later this year, set up potential approvals in 2027 for multi-billion-dollar markets. Tyvaso DPI hit record patient metrics, showing strong underlying demand despite competitive pressure. The organ manufacturing pipeline is advancing with clinical trials and two production facilities launching this year, following the recent Thymmune acquisition and a $1.5B buyback.
At the time of this announcement, UTHR was trading at $510.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22B. The 52-week trading range was $287.65 to $609.35. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: BusinessWire.